The modified market cap-weighted index tracks the performance of the largest and most liquid US-listed companies that generate at least 50% of their revenues from biotechnology. The pure-play index contains only companies which are engaged primarily in research and development as well as production, marketing and sales of drugs based on genetic analysis and diagnostic equipment. The MVIS US Listed Biotech 25 Index (MVBBH) has been licensed to underlie financial products with currently USD 497.4 million in assets under management.
Full MCap of at least 150 mln USD. Three month average-daily-trading volume of at least 1 mln USD at a review and also at the previous two reviews. At least 250,000 shares traded per month over the last six months at a review and also at the previous two reviews.
Pure-Play
Companies have to generate at least 50% revenues from biotechnology.
Diversification
Company weightings are capped at 20%.
Review
Semi-annually.
Index
Last Close
Open
Last
Change
Change (1Y)
Range (1Y)
4,133.54
4,133.54
-
-
62.51%
2,240.23 - 4,582.60
4,299.87
4,299.87
-
-
66.76%
2,273.72 - 4,764.62
5,835.36
5,835.36
-
-
68.43%
3,056.53 - 6,464.69
Timescale Slider
Symbol
IndexName
MVBBH
MVIS US Biotech 25 Price Index
MVBBHTR
MVIS US Biotech 25 Total Return Net Index
MVBBHTRG
MVIS US Biotech 25 Total Return Gross Index
NEWS & RESEARCH
Gain access to all Index Data and receive updates on market developments, index news and corporate announcements.
